Single dose study of pevifoscorvir in people with kidney impairment
Part of Digestive system, Infections clinical trials.
This study tests how a single dose of the study drug, pevifoscorvir, is processed in people with different levels of kidney function. It helps understand if the dose needs to be adjusted for people with kidney problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You weigh more than 110 pounds (50 kg)
- You have either normal kidney function or mild to moderate kidney problems (not on dialysis)
- You do not have a serious heart rhythm condition or long QT syndrome
- You do not have active hepatitis B, C, or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This Phase 1 study tests how two investigational medicines move through the body and how safe they are in people with different levels of liver impairment, compared with healthy volunteers. It may help doctors understand dosing and safety for people with liver problems.
This trial tests how the drug vorasidenib behaves in people with severe liver problems compared to healthy volunteers. It helps doctors understand if the drug needs different dosing for patients with liver disease.
This study tests how the body processes the experimental medicine PF-07328948 in people with different levels of kidney function. It may help find the right dose for people with kidney disease.
This trial tests a drug called Bepirovirsen for people with chronic hepatitis B who have low levels of the virus marker (HBsAg). It aims to see if the drug can help control the infection, and involves a liver biopsy to check the liver.
This study tests the safety and how the body processes very high doses of the antiviral drug favipiravir in healthy people. It helps find the highest dose that is still safe before testing in patients.
Hear when a new Chronic Hepatitis B Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.